Earnings Forecast Research on Endologix, Inc. (ELGX)

Endologix, Inc. has received $-0.18 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.24 while the top line estimate is $-0.14 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -127.5%.

Endologix, Inc. reported better than expected with a surprise EPS of 21.43% or $0.03 during its most recent quarterly earnings. The Actual EPS was $-0.11 compared to the Estimated EPS of $-0.14.

In the last quarter, Endologix, Inc. reported Annual Earnings of $-0.11. Based on the filings, last years Annual Earnings was, $-0.53. In the last Quarter, ELGX reported a surprise Earnings per Share of 21.43% . The consensus estimate for current quarter is $-0.18 and for the current fiscal year, the estimate is $-0.74. For the Next fiscal year, the estimate is $-0.65 based on the consensus.

Endologix, Inc. (NASDAQ:ELGX) : On Tuesday heightened volatility was witnessed in Endologix, Inc. (NASDAQ:ELGX) which led to swings in the share price. The stock opened for trading at $6.5 and hit $6.94 on the upside , eventually ending the session at $6.86, with a gain of 4.89% or 0.32 points. The heightened volatility saw the trading volume jump to 1,945,503 shares. The 52-week high of the share price is $14.495 and the company has a market cap of $567 million. The 52-week low of the share price is at $4.78 .

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.

Endologix,

Share this post

Leave a Reply